Arvinas (ARVN) Free Cash Flow (2017 - 2026)
Arvinas (ARVN) posted quarterly Free Cash Flow of -$70.5 million for Q1 2026, up 21.05% year-over-year from -$58.2 million in Q1 2025, and down 143.1% quarter-over-quarter from -$29.0 million in Q4 2025.
Powered by 
Analysis
Arvinas (ARVN) Free Cash Flow (2017 - 2026) Analysis & Trends
Arvinas' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$70.5 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 21.05% year-over-year to -$70.5 million; the TTM figure through Mar 2026 stood at -$255.3 million (down 0.95% YoY), while the FY2025 annual figure was -$274.1 million, down 4.98% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$70.5 million, down from -$29.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $49.5 million in Q2 2024, with the low at -$128.7 million in Q3 2024.
- The 5-year median for Free Cash Flow is -$83.2 million (2023), against an average of -$72.4 million.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow surged 155.43% in 2024, then plunged 295.15% in 2025.
- Arvinas' Free Cash Flow stood at -$71.0 million in 2022, then slipped by 17.18% to -$83.2 million in 2023, then retreated by 1.44% to -$84.4 million in 2024, then surged by 65.64% to -$29.0 million in 2025, then sank by 143.1% to -$70.5 million in 2026.
- Business Quant data shows ARVN's Free Cash Flow at -$70.5 million in Q1 2026, -$29.0 million in Q4 2025, and -$59.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - | -48.50 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -48.50 Mn |
| Mar 31, 2026 | -70.50 Mn |
| Dec 31, 2025 | -30.60 Mn |
| Sep 30, 2025 | -59.20 Mn |
| Jun 30, 2025 | -96.60 Mn |
| Mar 31, 2025 | -89.30 Mn |
| Dec 31, 2024 | -84.40 Mn |
| Sep 30, 2024 | -128.70 Mn |
| Jun 30, 2024 | 49.60 Mn |
| Mar 31, 2024 | -97.60 Mn |
| Dec 31, 2023 | -83.20 Mn |
| Sep 30, 2023 | -85.90 Mn |
| Jun 30, 2023 | -89.30 Mn |
| Mar 31, 2023 | -92.30 Mn |
| Dec 31, 2022 | -72.30 Mn |
| Sep 30, 2022 | -68.80 Mn |
| Jun 30, 2022 | -80.00 Mn |
| Mar 31, 2022 | -59.20 Mn |
| Dec 31, 2021 | -37.60 Mn |
| Sep 30, 2021 | 680.20 Mn |